Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate optimal dose and safety of the combination of
Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with
metastatic pancreatic cancer.